Celadon Partners Discloses Majority Stake in Senti Biosciences Following $40M Convertible Note Agreement

summarizeSummary

Celadon Partners will become the majority owner of Senti Biosciences with a 54.6% stake after converting initial convertible notes, signaling potential restructuring or M&A discussions.

check_boxKey Events

• Investor Acquires Majority Control

  Celadon Partners will beneficially own 54.6% of Senti Biosciences' common stock upon the conversion of the initial $10.0 million tranche of convertible notes, making them the majority shareholder.

• Potential Restructuring and M&A

  Celadon Partners intends to engage in preliminary discussions with the company regarding potential restructuring or merger and acquisition transactions.

• Highly Dilutive Financing Confirmed

  The ownership increase stems from the previously disclosed $40.0 million convertible note agreement, with an initial conversion price of $0.6261 per share, significantly below the current market price.

auto_awesomeAnalysis

This Schedule 13D/A from Celadon Partners confirms their beneficial ownership will increase to 54.6% of Senti Biosciences' common stock upon the conversion of the initial $10.0 million tranche of convertible notes. This effectively grants Celadon majority control of the company. The filing also indicates Celadon's intent to engage in preliminary discussions regarding potential restructuring or merger and acquisition transactions, signaling a significant strategic shift for Senti Biosciences under new control. This follows the company's 8-K on May 1, 2026, which disclosed the highly dilutive $40.0 million convertible note agreement with Celadon.